Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant PTK7 (Cofetuzumab Biosimilar) anticorps

Cet anticorps Humanized Monoclonal détecte spécifiquement PTK7 (Cofetuzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7795145

Aperçu rapide pour Recombinant PTK7 (Cofetuzumab Biosimilar) anticorps (ABIN7795145)

Antigène

PTK7 (Cofetuzumab Biosimilar)

Type d'anticorp

Recombinant Antibody

Reactivité

Humain

Hôte

  • 2
  • 1
  • 1
Humanized

Clonalité

  • 3
  • 1
Monoclonal

Conjugué

  • 4
Cet anticorp PTK7 (Cofetuzumab Biosimilar) est non-conjugé

Application

  • 2
  • 2
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité

Research Grade
  • Expression System

    Mammalian cells

    Fonction

    Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody

    Attributs du produit

    What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.

    Purification

    Protein A or G affinity column

    Pureté

    >95 % by reducing SDS-PAGE

    niveau d'endotoxine

    < 1 EU per 1 mg of the protein by the LAL method

    Immunogène

    Human PTK7
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    > 3 mg/mL

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Antigène

    PTK7 (Cofetuzumab Biosimilar)

    Autre désignation

    Cofetuzumab Biosimilar

    Classe de substances

    Biosimilar
Vous êtes ici:
Chat with us!